Claims for Patent: 8,101,773

Summary for Patent: 8,101,773

Title:	Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer
Abstract:	The compound 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoy- l)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide and alternative forms thereof (e.g., salts, solvates, hydrates, prodrugs, polymorphs and metabolites); pharmaceutical compositions which contain them; and methods for treating cancer using them.
Inventor(s):	Smith; Roger (Chester Springs, PA), Nagarathnam; Dhanapalan (Bethany, CT)
Assignee:	Bayer Healthcare LLC (Tarrytown, NY)
Application Number:	12/520,609
Patent Claims:	1. A compound having the formula: ##STR00022## which is 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}-carbamo- yl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof or an ester prodrug thereof. 2. A compound of claim 1 wherein the prodrug is selected from the group consisting of: a) 3-(3-tert-Butyl-5-{[(2-fluoro-4-{[(2-(methylcarbamoyl)pyridin-4-yl]oxy}ph- enyl)carbamoyl]amino}-1 H-pyrazol-1-yl)benzyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]D valinate of the formula: ##STR00023## b) 3-(3-tert-Butyl-5-{[(2-fluoro-4-{[(2-(methylcarbamoyl)pyridin-4-yl]oxy}ph- enyl)-carbamoyl]amino}-1H-pyrazol-1-yl)benzyl D-valinate of the formula: ##STR00024## c) 3-(3-tert-Butyl-5-{[(2-fluoro-4-{[2-(methylcarbamoyl)pyridin-4-yl]oxy}-ph- enyl)carbamoyl]amino}-1H-pyrazol-1-yl)benzyl L-valinate of the formula: ##STR00025## d) 3-(3-tert-Butyl-5-{[(2-fluoro-4-{[2-(methylcarbamoyl)pyridin-4-yl]oxy}-ph- enyl)carbamoyl]amino}-1H-pyrazol-1-yl)benzyl acetate of the formula: ##STR00026## e) di-tert-butyl 3-(3-tert-butyl-5-{[(2-fluoro-4-{[2-(methylcarbamoyl)pyridin-4-yl]oxy}phe- nyl)carbamoyl]amino}-1H-pyrazol-1-yl)benzyl phosphate of the formula: ##STR00027## f) 3-(3-tert-Butyl-5-{[(2-fluoro-4-{[2-(methylcarbamoyl)pyridin-4-yl]oxy}-ph- enyl)carbamoyl]amino}-1H-pyrazol-1-yl)benzyl dihydrogen phosphate dihydrochloride of the formula: ##STR00028## g) 4-{[3-tert-Butyl-5-{[(2-fluoro-4-{[2-(methylcarbamoyl)pyridin-4-yl]oxy}-p- henyl)carbamoyl]amino}-1H-pyrazol-1-yl)benzyl]oxy}-4-oxobutanoic acid of the formula: ##STR00029## h) 3-(3-tert-Butyl-5-{[(2-fluoro-4-{[2-(methylcarbamoyl)pyridin-4-yl]oxy}phe- nyl)carbamoyl]amino}-1H-pyrazol-1-yl)benzyl methoxyacetate of the formula: ##STR00030## i) 3-(3-tert-butyl-5-{[(2-fluoro-4{[2-(methylcarbamoyl)pyridin-4-yl]oxy}phen- yl)carbamoyl]amino}-1H-pyrazol-1-yl)benzyl propionate of the formula: ##STR00031## j) 3-(3-tert-Butyl-5-{[(2-fluoro-4-{[2-(methylcarbamoyl)pyridin-4-yl]oxy}phe- nyl)carbamoyl]amino }-1H-pyrazol-1-yl)benzyl 3-methylbutanoate of the formula: ##STR00032## 3. A compound of claim 1 wherein the salt is selected from the group consisting of a) 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoy- l)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, bis(4-methylbenzenesulfonate)salt, b) 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoy- l)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, dimethane-sulfonate salt, c) 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoy- l)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, dihydrochloride salt, d) 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl- }carbamoyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, bis(benzene-sulfonate) salt, e) 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoy- l)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, dihydrogen bromide salt and f) 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoy- l)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, hydrogen sulfate salt. 4. A pharmaceutical composition comprising: a compound having the formula: ##STR00033## which is 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}-carbamo- yl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof, or an ester prodrug thereof. 5. A pharmaceutical composition comprising a compound of claim 2 and a physiologically acceptable carrier. 6. A pharmaceutical composition comprising a compound of claim 3 and a physiologically acceptable carrier. 7. A method of treating hyper-proliferative disorders comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1. 8. A method of treating hyper-proliferative disorders comprising administering to a mammal in need thereof a therapeutically effective amount of a composition of claim 4. 9. A method according to claim 8, wherein said hyper-proliferative disorder is cancer. 10. A method according to claim 9, wherein said cancer is of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and/or neck, thyroid, parathyroid and/or their distant metastases. 11. A method according to claim 9, wherein said cancer is lymphoma, sarcoma, or leukemia. 12. A method according to claim 10, wherein said breast cancer is invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, or lobular carcinoma in situ; said respiratory tract cancer is small-cell lung carcinoma, non-small-cell lung carcinoma, bronchial adenoma or pleuropulmonary blastoma; said brain cancer is a tumor of the brain stem, hypophtalmic glioma, cerebellar astrocytoma, cerebral astrocytoma, medulloblastoma, ependymoma, neuroectodermal or pineal tumor; said tumor of the male reproductive organ is a prostate or testicular cancer; said cancer of the female reproductive organ is endometrial, cervical, ovarian, vaginal, vulvar, or sarcoma of the uterus; said cancer of the digestive tract is anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small-intestine or salivary gland; said cancer of the urinary tract is bladder, penile, kidney, renal pelvis, ureter or urethral; said eye cancer is intraocular melanoma or retinoblastoma; said liver cancer is hepatocellular carcinoma, liver cell carcinomas with or without fibrolamellar variant, cholangiocarcinoma or mixed hepatocellular cholangiocarcinoma; said skin cancer is squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer or non-melanoma skin cancer; said head-and-neck cancer is laryngeal, hypopharyngeal , nasopharyngeal , oropharyngeal, lip or oral cavity cancer; said lymphoma is AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Hodgkin's disease or lymphoma of the central nervous system; said sarcomas is a sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma or rhabdomyosarcoma; said leukemia is acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia or hairy cell leukemia 13. A method of treating angiogenesis disorders comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1. 14. A composition of claim 4, further including an anti-hyper-proliferative agent. 15. A composition of claim 14, wherein said anti -hyper-proliferative agent is epothiline or its derivative, irinotecan, raloxifen or topotecan. 16. A composition of claim 4, wherein said additional pharmaceutical agent is aldesleukin, alendronic acid, alfaferone, alitretinoin, allopurinol, aloprim, aloxi, altretamine, aminoglutethimide, amifostine, amrubicin, amsacrine, anastrozole, anzmet, aranesp, arglabin, arsenic trioxide, aromasin, 5-azacytidine, azathioprine, BCG or tice BCG, bestatin, betamethasone acetate, betamethasone sodium phosphate, bexarotene, bleomycin sulfate, broxuridine, bortezomib, busulfan, calcitonin, campath, capecitabine, carboplatin, casodex, cefesone, celmoleukin, cerubidine, chlorambucil, cisplatin, cladribine, cladribine, clodronic acid, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, DAUNOXOME.RTM. (daunorubicin), decadron, decadron phosphate, delestrogen, denileukin diftitox, depo-medrol, deslorelin, dexrazoxane, diethylstilbestrol, diflucan, docetaxel, doxifluridine, doxorubicin, dronabinol, DW-166HC, eligard, elitek, ellence, emend, epirubicin, epoetin alfa, EPOGEN.RTM. (epotin-alpha), eptaplatin, ergamisol, estrace, estradiol, estramustine phosphate sodium, ethinyl estradiol, ethyol, etidronic acid, etopophos, etoposide, fadrozole, FARESTON.RTM. (Toremitene), filgrastim, finasteride, fligrastim, floxuridine, fluconazole, fludarabine, 5-fluorodeoxyuridine monophosphate, 5-fluorouracil (5-FU), fluoxymesterone, flutamide, formestane, fosteabine, fotemustine, fulvestrant, gammagard, gemcitabine, gemtuzumab, GLEEVEC.RTM. (imatinib mesylate), GLIADEL.RTM. (wafer), goserelin, granisetron HC1, histrelin, hycamtin, hydrocortone, eyrthro-hydroxynonyladenine, hydroxyurea, ibritumomab tiuxetan, idarubicin, ifosfamide, interferon alpha, interferon-alpha 2, interferon alfa-2A, interferon alfa-2B, interferon alfa-n1, interferon alfa-n3, interferon beta, interferon gamma-1a, interleukin-2, INTRON-A (interferon alfa-2b, recombinant) iressa, irinotecan, kytril, lentinan sulphate, letrozole, leucovorin, leuprolide, leuprolide acetate, levamisole, levofolinic acid calcium salt, levothroid, LEVOXYL .RTM. (levothyroxine sodium tablets,), lomustine, lonidamine, marinol, mechlorethamine, mecobalamin, medroxyprogesterone acetate, megestrol acetate, melphalan, MENEST.RTM. (esterified estrogens), 6 -mercaptopurine, Mesna, methotrexate, metvix, miltefosine, minocycline, mitomycin C, mitotane, mitoxantrone, MODRENAL.RTM. (trilostane), MYOCET .RTM. (non-pegylated liposomal doxorubicin), nedaplatin, neulasta, neumega, neupogen, nilutamide, NOLVADEX.RTM. (tamoxifen citrate), NSC-631570, OCT-43, octreotide, ondansetron HC1, orapred, oxaliplatin, paclitaxel, pediapred, pegaspargase, PEAGASYS (peginterferon alfa-2a), pentostatin, picibanil, pilocarpine HC1, pirarubicin, plicamycin, porfimer sodium, prednimustine, prednisolone, prednisone, PREMARIN.RTM. (conjugated estrogen tablets), procarbazine, procrit, raltitrexed, rebif, rhenium-186 etidronate, rituximab, roferon-A, romurtide, salagen, sandostatin, sargramostim, semustine, sizofiran, sobuzoxane, solu-medrol, sparfosic acid, stem-cell therapy, streptozocin, strontium-89 chloride, synthroid, tamoxifen, tamsulosin, tasonermin, tastolactone, TAXOTERE.RTM. (docetaxel), teceleukin, temozolomide, teniposide, testosterone propionate, TESTRED.RTM. (Methyltestosterone), thioguanine, thiotepa, thyrotropin, tiludronic acid, topotecan, toremifene, tositumomab, trastuzumab, treosulfan, tretinoin, trexall, trimethylmelamine, trimetrexate, triptorelin acetate, triptorelin pamoate, UFT, uridine, valrubicin, vesnarinone, vinblastine, vincristine, vindesine, vinorelbine, virulizin, zinecard, zinostatin stimalamer, ZOFRAN.RTM. (ondansetron), ABI-007, acolbifene, actimmune, affinitak, aminopterin, arzoxifene, asoprisnil, atamestane, atrasentan, BAY 43-9006 (sorafenib), avastin, CCI-779, CDC-501, CELEBREX.RTM. (anti-inflamatory), cetuximab, crisnatol, cyproterone acetate, decitabine, DN-101, doxorubicin-MTC, dSLIM, dutasteride, edotecarin, eflornithine, exatecan, fenretinide, histamine dihydrochloride, histrelin hydrogel implant, holmium-166 DOTMP, ibandronic acid, interferon gamma, intron-PEG, ixabepilone, keyhole limpet hemocyanin, L-651582, lanreotide, lasofoxifene, libra, lonafarnib, miproxifene, minodronate, MS-209, liposomal MTP-PE, MX-6, nafarelin, nemorubicin, neovastat, nolatrexed, oblimersen, onco-TCS, osidem, paclitaxel polyglutamate, pamidronate disodium, PN-401, QS-21, quazepam, R-1549, raloxifene, ranpirnase, 13-cis -retinoic acid, satraplatin, seocalcitol, T-138067, TARCEVA.RTM. (erlotinib), taxoprexin, thymosin alpha 1, tiazofurine, tipifarnib, tirapazamine, TLK-286, toremifene, TransMID-107R, valspodar, vapreotide, vatalanib, verteporfin, vinflunine, Z-100, zoledronic acid or combinations thereof.

Details for Patent 8,101,773

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2026-12-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2026-12-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2026-12-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2026-12-20
Baxalta Us Inc.	GAMMAGARD, GAMMAGARD S/D, IVEEGAM	immune globulin intravenous (human)	For Injection	103133	02/18/1986		2026-12-20
Baxalta Us Inc.	GAMMAGARD, GAMMAGARD S/D, IVEEGAM	immune globulin intravenous (human)	For Injection	103133	07/27/2000		2026-12-20